These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 38236558)

  • 1. PARP Inhibitors in Breast Cancer: a Short Communication.
    Daly GR; AlRawashdeh MM; McGrath J; Dowling GP; Cox L; Naidoo S; Vareslija D; Hill ADK; Young L
    Curr Oncol Rep; 2024 Feb; 26(2):103-113. PubMed ID: 38236558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Treatment Strategies to Overcome PARP Inhibitor Resistance.
    Soung YH; Chung J
    Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    Papa A; Caruso D; Strudel M; Tomao S; Tomao F
    J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.
    Mehta P; Bothra SJ
    Adv Genet; 2021; 108():35-80. PubMed ID: 34844716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS; Gillard M; Lipkowitz S; Lee JM
    Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status.
    Wu Y; Xu S; Cheng S; Yang J; Wang Y
    J Ovarian Res; 2023 Jan; 16(1):6. PubMed ID: 36611214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
    Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?
    Incorvaia L; Perez A; Marchetti C; Brando C; Gristina V; Cancelliere D; Pivetti A; Contino S; Di Giovanni E; Barraco N; Bono M; Giurintano A; Bazan Russo TD; Gottardo A; Cutaia S; Pedone E; Peri M; Corsini LR; Fanale D; Galvano A; Scambia G; Badalamenti G; Russo A; Bazan V
    Cancer Treat Rev; 2023 Dec; 121():102650. PubMed ID: 37939446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.
    Xia M; Guo Z; Hu Z
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34066020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
    Oh SY; Rahman S; Sparano JA
    Expert Opin Pharmacother; 2021 Jun; 22(8):981-1003. PubMed ID: 33646064
    [No Abstract]   [Full Text] [Related]  

  • 16. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M
    Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitors in ovarian cancer.
    Goldlust IS; Guidice E; Lee JM
    Semin Oncol; 2024; 51(1-2):45-57. PubMed ID: 38262776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
    Li J; Li Q; Zhang L; Zhang S; Dai Y
    Biomed Pharmacother; 2023 Jan; 157():114028. PubMed ID: 36410122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N; Wang Y; Deng W; Lin SH
    Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.